glp-1 advantage book The Protocol The GLP-1 Handbook by Ian

J.BonnerT

Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report

94% reduction in progression from pre diabetes to type 2 diabetes with tirzepatide.** **Based on a three-year clinical trial study (176-week treatment period) sponsored by Eli Lilly and Company, weekly injections of tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with prediabetes who were overweight or obese compared to placebo

Table of Contents Why this conversation matters Guest snapshot Peptides 101 Safe, practical peptide picks Regulatory and safety landscape NAD, exosomes, and their place GLP1 medications and microdosing Practical care pathways Gut health as the foundation Hormone replacement therapy (HRT) for midlife women Exercise, resistance training, and practical tools Supplements and small wins Finding a clinician: what to look for Common myths and straightforward truths Patient stories and the human side Practical checklist for someone considering peptides or GLP1s Resources FAQ Final practical notes from our clinical experience Where to learn more Closing practical tip Why this conversation matters We are living through a moment when new metabolic and regenerative tools are more accessible than ever

Before and after tirzepatide results from real users generally align with these trial findings, though individual variation remains significant

Diabetes Care, 26 (11), 29772982